Concerning the operation of medical spas involving the use of prescription drugs, and, in connection therewith, establishing that certain actions by medical spas are unfair or deceptive trade practices under the "Colorado Consumer Protection...
SB 26-130 would create a new section of the Colorado Consumer Protection Act covering medical spas that use prescription drugs for cosmetic, aesthetic, wellness, longevity, or lifestyle services. It defines a “medical spa” broadly and makes a range of practices unfair or deceptive trade practices, including obtaining drugs from unauthorized sources, improper storage or administration, allowing practitioners to act outside their scope, failing to maintain safeguards against contamination or diversion, making false or misleading claims about drug safety or FDA approval, failing to provide clinical oversight by a licensed prescriber, and failing to keep records of serious adverse events.
The bill also requires medical spas to maintain internal records of serious adverse events involving prescription drugs and to produce those records to the attorney general or a district attorney upon request for enforcement purposes. It authorizes the attorney general to adopt rules to implement the section, but it does not create a new licensing or inspection regime. The bill would take effect after the standard post-session period unless referred to voters, and it would apply only to conduct occurring on or after the effective date.
The bill would amend Colorado law by adding section 6-1-741 to the Colorado Revised Statutes and expanding the Colorado Consumer Protection Act to specifically regulate medical spas that administer prescription drugs. It gives the attorney general and district attorneys direct enforcement authority over the listed practices, while preserving the role of existing professional licensing boards and avoiding a separate state registration or inspection program. Medical spas, owners, and practitioners using prescription drugs such as injectables, fillers, hormone therapies, and nutrient therapies would be subject to the new standards and recordkeeping obligations.
The available context suggests the bill was treated as a consumer-protection and patient-safety measure aimed at addressing risks in a growing medical spa industry. The legislative declaration emphasizes unsafe practices, misleading marketing, and the need for enforceable standards without creating a new regulatory bureaucracy. However, the bill was postponed indefinitely in the Senate Health & Human Services Committee, indicating that it did not advance and may have faced unresolved concerns or insufficient support.
The main points of contention appear to center on how broadly the bill would reach medical spa operations and whether consumer-protection enforcement is the right tool for regulating clinical practices. Potential concerns include the scope of the definition of medical spa, the requirement for a licensed provider with prescriptive authority to provide oversight, the obligation to produce adverse-event records to prosecutors, and the risk that the bill could overlap with or intrude on existing professional licensing and medical practice rules. Supporters likely viewed these provisions as necessary to prevent unsafe or deceptive practices, while opponents or undecided members may have been concerned about regulatory burden, ambiguity, or enforcement consequences.